Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity

Oncotarget

Volumn 6, Issue 13, 2015, Pages 10746-10758

  Frankum, Jessica ^a   Moudry, Pavel ^b   Brough, Rachel ^a   Hodny, Zdenek ^c   Ashworth, Alan ^a   Bartek, Jiri ^b,c   Lord, Christopher J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

CBLC; DNA damage response; PARP inhibitors; RNA interference screens; Ubiquitin proteasome system

Indexed keywords

OLAPARIB; SHORT HAIRPIN RNA; TUMOR MARKER; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; CBL PROTEIN; CBLC PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PARP1 PROTEIN, HUMAN; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ARTICLE; BREAST CANCER CELL LINE; CBLC GENE; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; GENE IDENTIFICATION; GENE SILENCING; GENETIC SCREENING; GENOME ANALYSIS; HUMAN; HUMAN CELL; MICROSCOPY; RECOMBINATION REPAIR; RNA INTERFERENCE; SCORING SYSTEM; SENSITIVITY ANALYSIS; TUMOR GENE; UBIQUITINATION; BREAST NEOPLASMS; CELL SURVIVAL; DNA REPAIR; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETIC RECOMBINATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

BRCA2 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHTHALAZINES; PIPERAZINES; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-CBL; RECOMBINATION, GENETIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; UBIQUITINATION;

EID: 84929643068     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3628     Document Type: Article

References (41)

1. De Vos M, Schreiber V and Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol. 2012; 84(2):137-146.
2. Lord CJ, Tutt AN and Ashworth A. Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors. Annu Rev Med. 2015; 66:455-470.
3. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC and Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-921.
4. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-917.
5. PARP inhibitor approved, despite vote. Nat Biotechnol. 2015; 33(2):116.
6. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S and Pommier Y. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72(21):5588-5599.
7. Pettitt SJ, Rehman FL, Bajrami I, Brough R, Wallberg F, Kozarewa I, Fenwick K, Assiotis I, Chen L, Campbell J, Lord CJ and Ashworth A. A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS One. 2013; 8(4):e61520.
8. Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res. 2014; 74(1):287-297.
9. Jackson SP and Durocher D. Regulation of DNA damage responses by ubiquitin and SUMO. Mol Cell. 2013; 49(5):795-807.
10. Lukas J, Lukas C and Bartek J. More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. Nat Cell Biol. 2011; 13(10):1161-1169.
11. Nishi R, Wijnhoven P, le Sage C, Tjeertes J, Galanty Y, Forment JV, Clague MJ, Urbe S and Jackson SP. Systematic characterization of deubiquitylating enzymes for roles in maintaining genome integrity. Nat Cell Biol. 2014; 16(10):1016-1026, 1011-1018.
12. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH and de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2):123-134.
13. Moudry P, Lukas C, Macurek L, Hanzlikova H, Hodny Z, Lukas J and Bartek J. Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage. Cell Cycle. 2012; 11(8):1573-1582.
14. Doil C, Mailand N, Bekker-Jensen S, Menard P, Larsen DH, Pepperkok R, Ellenberg J, Panier S, Durocher D, Bartek J, Lukas J and Lukas C. RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell. 2009; 136(3):435-446.
15. Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, Wilm M, Muir TW and Muller J. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature. 2010; 465(7295):243-247.
16. Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther. 2013; 12(6):1002-1015.
17. Khoronenkova SV, Dianova, II, Ternette N, Kessler BM, Parsons JL and Dianov GL. ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage. Mol Cell. 2012; 45(6):801-813.
18. Swaminathan G and Tsygankov AY. The Cbl family proteins: ring leaders in regulation of cell signaling. J Cell Physiol. 2006; 209(1):21-43.
19. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC and Ashworth A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006; 66(16):8109-8115.
20. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S and Pommier Y. GammaH2AX and cancer. Nat Rev Cancer. 2008; 8(12):957-967.
21. Saeki H, Siaud N, Christ N, Wiegant WW, van Buul PP, Han M, Zdzienicka MZ, Stark JM and Jasin M. Suppression of the DNA repair defects of BRCA2-deficient cells with heterologous protein fusions. Proc Natl Acad Sci U S A. 2006; 103(23):8768-8773.
22. Keane MM, Ettenberg SA, Nau MM, Banerjee P, Cuello M, Penninger J and Lipkowitz S. cbl-3: a new mammalian cbl family protein. Oncogene. 1999; 18(22):3365-3375.
23. Ryan PE, Kales SC, Yadavalli R, Nau MM, Zhang H and Lipkowitz S. Cbl-c ubiquitin ligase activity is increased via the interaction of its RING finger domain with a LIM domain of the paxillin homolog, Hic 5. PLoS One. 2012; 7(11):e49428.
24. Tsui CC and Pierchala BA. CD2AP and Cbl-3/Cbl-c constitute a critical checkpoint in the regulation of ret signal transduction. J Neurosci. 2008; 28(35):8789-8800.
25. Kim M, Tezuka T, Tanaka K and Yamamoto T. Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent protein degradation. Oncogene. 2004; 23(9):1645-1655.
26. Calco GN, Stephens OR, Donahue LM, Tsui CC and Pierchala BA. CD2-associated protein (CD2AP) enhances casitas B lineage lymphoma-3/c (Cbl-3/c)-mediated Ret isoform-specific ubiquitination and degradation via its amino-terminal Src homology 3 domains. J Biol Chem. 2014; 289(11):7307-7319.
27. Kales SC, Nau MM, Merchant AS and Lipkowitz S. Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A. PLoS One. 2014; 9(1):e87116.
28. Desai LP, Zhou Y, Estrada AV, Ding Q, Cheng G, Collawn JF and Thannickal VJ. Negative regulation of NADPH oxidase 4 by hydrogen peroxide-inducible clone 5 (Hic-5) protein. J Biol Chem. 2014; 289(26):18270-18278.
29. Hubackova S, Krejcikova K, Bartek J, Hodny Z. IL1-and TGFbeta-Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced, and drug-induced paracrine 'Bystander senescence'. Aging (Albany NY) 4:932-51, 2012.
30. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1.
31. Naramura M, Nadeau S, Mohapatra B, Ahmad G, Mukhopadhyay C, Sattler M, Raja SM, Natarajan A, Band V and Band H. Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. Oncotarget. 2011; 2(3):245-250.
32. Fiore F, Estebe B, Gibier P, Orsoni JC, Courbard JR, Chodosh LA, Birnbaum D and Delapeyriere O. Abnormal mammary gland development in MMTV-CBLC transgenic mouse. In Vivo. 2009; 23(2):225-228.
33. Griffiths EK, Sanchez O, Mill P, Krawczyk C, Hojilla CV, Rubin E, Nau MM, Khokha R, Lipkowitz S, Hui CC and Penninger JM. Cbl-3-deficient mice exhibit normal epithelial development. Mol Cell Biol. 2003; 23(21):7708-7718.
34. Bouwman P and Jonkers J. Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility. Cell Cycle. 2008; 7(17):2647-2653.
35. Choi YE, Battelli C, Watson J, Liu J, Curtis J, Morse AN, Matulonis UA, Chowdhury D and Konstantinopoulos PA. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget. 2014; 5(9):2678-2687.
36. Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment Cell Cycle, 2012: 11: 3837-3850.
37. Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S and Bhalla KN. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget. 2014; 5(14):5637-5650.
38. Majuelos-Melguizo J, Rodriguez MI, Lopez-Jimenez L, Rodriguez-Vargas JM, Martin-Consuegra JM, Serrano-Saenz S, Gavard J, de Almodovar JM and Oliver FJ. PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma. Oncotarget. 2014.
39. Watanabe S, Watanabe K. Akimov V, Bartkova J, Blagoyev B, Lukas J, Bartek J. JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1 mediated chromatin response to DNA breaks. Nature Struct. Mol. Biol., 2013; 20:1425-33.
40. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der GH, Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., Haffty, B,G., Tommiska, J., Blomqvist, C., Drapkin, R., Adams, D.J., Nevanlinna, H.,Bartek, J., Tarsounas, M., Ganesan, S., Jonkers, J.. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010; 17:688-95, 2010.
41. Bouwman P, Jonkers J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res. 2014; 20(3):540-7.